No abstract

No abstract

One hundred and twelve renal masses, whose histology was confirmed at operation, as well as renal vein thrombosis and renal infiltration, were examined by urography, sonography, CT and angiography. In general the results showed good agreement. For the diagnosis of the type of tumour, its size, infiltration into the renal capsule, demonstration of regional lymph node metastases and infiltration into neighbouring organs and for the diagnosis of liver metastases, CT was superior to the other methods.

The radiological appearance of 6 posterior epidiaphragmatic fatty tissue masses in MRI and CT is reported. The differential diagnostic considerations of lipoma, herniation or dystopia and the value of imaging techniques are discussed.

Purpose/Objective(s): Radiotherapy (RT) has been an important component of treatment in Hodgkin lymphoma (HL) for the past six decades. Before the routine use of combined-modality regimens and conformal RT techniques, radiation fields covered larger elective lymphatic volumes leading to high doses to non-targeted normal tissues. The purpose of this study was to investigate the incidence of cardiac events and secondary malignancies in HL patients who received RT at our institution. Materials/Methods: Between June 1982 and April 1995, 178 patients received primary RT with or without chemotherapy with curative intent at our institution for de novo HL. Patient age ranged from 6 to 82 years (median, 25 years), with 109 (61%) males and 69 (39%) females. The potential length of follow-up was 20 years. Per Ann Arbor staging, 39 (22%), 86 (48%), 37 (21%), and 16 (9%) patients were staged at I, II, III and IV, respectively. Overall, radiation field design included mantle irradiation (13%; nZ23), subtotal nodal irradiation (38%; nZ68), total nodal irradiation (41%; nZ73), and involved-field radiotherapy (8%; nZ14), respectively. In addition to RT, 102 (58%) patients received chemotherapy. Charts were retrospectively reviewed, and patients were contacted via telephone under an IRB-approved protocol. Adverse events were recorded using the Common Terminology for Adverse Events, version 3.0. Results: The median follow-up time was 22 years (range, 2 months to 33 years). At last follow-up, 102 (57%) patients were alive without evidence of disease, while 12 (7%), 7 (4%), 9 (5%), 15 (8%), and 33 (19%) patients died from disease progression, acute complications from RT, cardiac disease, secondary cancer, and other causes, respectively. Forty-six grade3 cardiac events were reported in 38 (21%) patients, including coronary artery disease (nZ26), cardiac valvular disease (nZ12), and cardiomyopathy (nZ8). Thirty-nine in-field secondary malignancies were reported in 33 (19%) patients after RT, with the most common sites being breast (nZ8), head and neck (nZ7), and gastrointestinal organs (nZ5). Overall, 65 (37%) patients suffered from either an in-field secondary malignancy or cardiac disease. Conclusion: Over one-third of the cohort experienced a clinically significant cardiac event or secondary malignancy between 20 and 30 years after radiation therapy for HL. This study underscores the need for improved treatment strategies, conformal radiation therapy techniques, and continued long-term follow-up for patients with HL.